首页 > 最新文献

Annals of Eye Science最新文献

英文 中文
Hyperspectral autofluorescence characterization of drusen and sub-RPE deposits in age-related macular degeneration. 老年性黄斑变性中dren和亚rpe沉积物的高光谱自身荧光特征。
Pub Date : 2021-03-01 Epub Date: 2021-03-15 DOI: 10.21037/aes-20-12
Yuehong Tong, Thomas Ach, Christine A Curcio, R Theodore Smith

Background: Soft drusen and basal linear deposit (BLinD) are two forms of the same extracellular lipid rich material that together make up an Oil Spill on Bruch's membrane (BrM). Drusen are focal and can be recognized clinically. In contrast BLinD is thin and diffusely distributed, and invisible clinically, even on highest resolution OCT, but has been detected on en face hyperspectral autofluorescence (AF) imaging ex vivo. We sought to optimize histologic hyperspectral AF imaging and image analysis for recognition of drusen and sub-RPE deposits (including BLinD and basal laminar deposit), for potential clinical application.

Methods: Twenty locations specifically with drusen and 12 additional locations specifically from fovea, perifovea and mid-periphery from RPE/BrM flatmounts from 4 AMD donors underwent hyperspectral AF imaging with 4 excitation wavelengths (λex 436, 450, 480 and 505 nm), and the resulting image cubes were simultaneously decomposed with our published non-negative matrix factorization (NMF). Rank 4 recovery of 4 emission spectra was chosen for each excitation wavelength.

Results: A composite emission spectrum, sensitive and specific for drusen and presumed sub-RPE deposits (the SDr spectrum) was recovered with peak at 510-520 nm in all tissues with drusen, with greatest amplitudes at excitations λex 436, 450 and 480 nm. The RPE spectra of combined sources Lipofuscin (LF)/Melanolipofuscin (MLF) were of comparable amplitude and consistently recapitulated the spectra S1, S2 and S3 previously reported from all tissues: tissues with drusen, foveal and extra-foveal locations.

Conclusions: A clinical hyperspectral AF camera, with properly chosen excitation wavelengths in the blue range and a hyperspectral AF detector, should be capable of detecting and quantifying drusen and sub-RPE deposits, the earliest known lesions of AMD, before any other currently available imaging modality.

背景:软瘤和基底线性沉积(BLinD)是两种形式的细胞外富脂物质,它们共同构成了布鲁氏膜上的溢油(BrM)。结节是局灶性的,可在临床上识别。相比之下,BLinD呈薄而弥漫性分布,即使在最高分辨率的OCT下也不可见,但在离体高光谱自体荧光(AF)成像中可以检测到。我们试图优化组织高光谱AF成像和图像分析,以识别dren和亚rpe沉积物(包括BLinD和基底层流沉积物),以用于潜在的临床应用。方法:对4例AMD供体RPE/BrM平板支架上的20个特异病灶和12个特异病灶,分别在4种激发波长(λex 436、450、480和505 nm)下进行高光谱自动对焦成像,并采用非负矩阵分解(NMF)方法对图像立方体进行分解。每个激发波长选取4个发射光谱的4阶恢复。结果:在所有含drusen的组织中均获得了对drusen和推定亚rpe矿床敏感且特异的复合发射光谱(SDr光谱),其峰值在510 ~ 520 nm处,在λ ex436、450和480 nm处振幅最大。联合源脂褐素(LF)/黑脂褐素(MLF)的RPE光谱具有相当的振幅,并且一致地再现了先前报道的所有组织的光谱S1、S2和S3:具有结节、中央凹和中央凹外位置的组织。结论:临床高光谱AF相机,在适当选择蓝色范围内的激发波长和高光谱AF检测器,应该能够检测和量化黄斑变性和亚rpe沉积,这是AMD最早已知的病变,比任何其他现有的成像方式都要早。
{"title":"Hyperspectral autofluorescence characterization of drusen and sub-RPE deposits in age-related macular degeneration.","authors":"Yuehong Tong,&nbsp;Thomas Ach,&nbsp;Christine A Curcio,&nbsp;R Theodore Smith","doi":"10.21037/aes-20-12","DOIUrl":"https://doi.org/10.21037/aes-20-12","url":null,"abstract":"<p><strong>Background: </strong>Soft drusen and basal linear deposit (BLinD) are two forms of the same extracellular lipid rich material that together make up an Oil Spill on Bruch's membrane (BrM). Drusen are focal and can be recognized clinically. In contrast BLinD is thin and diffusely distributed, and invisible clinically, even on highest resolution OCT, but has been detected on <i>en face</i> hyperspectral autofluorescence (AF) imaging <i>ex vivo</i>. We sought to optimize histologic hyperspectral AF imaging and image analysis for recognition of drusen and sub-RPE deposits (including BLinD and basal laminar deposit), for potential clinical application.</p><p><strong>Methods: </strong>Twenty locations specifically with drusen and 12 additional locations specifically from fovea, perifovea and mid-periphery from RPE/BrM flatmounts from 4 AMD donors underwent hyperspectral AF imaging with 4 excitation wavelengths (λ<sub>ex</sub> 436, 450, 480 and 505 nm), and the resulting image cubes were simultaneously decomposed with our published non-negative matrix factorization (NMF). Rank 4 recovery of 4 emission spectra was chosen for each excitation wavelength.</p><p><strong>Results: </strong>A composite emission spectrum, sensitive and specific for drusen and presumed sub-RPE deposits (the SDr spectrum) was recovered with peak at 510-520 nm in all tissues with drusen, with greatest amplitudes at excitations λ<sub>ex</sub> 436, 450 and 480 nm. The RPE spectra of combined sources Lipofuscin (LF)/Melanolipofuscin (MLF) were of comparable amplitude and consistently recapitulated the spectra S1, S2 and S3 previously reported from all tissues: tissues with drusen, foveal and extra-foveal locations.</p><p><strong>Conclusions: </strong>A clinical hyperspectral AF camera, with properly chosen excitation wavelengths in the blue range and a hyperspectral AF detector, should be capable of detecting and quantifying drusen and sub-RPE deposits, the earliest known lesions of AMD, before any other currently available imaging modality.</p>","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"6 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/82/nihms-1684628.PMC8009528.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25536760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Retinal imaging in inherited retinal diseases. 遗传性视网膜疾病的视网膜成像。
Pub Date : 2020-09-01 Epub Date: 2020-09-15 DOI: 10.21037/aes-20-81
Michalis Georgiou, Kaoru Fujinami, Michel Michaelides

Inherited retinal diseases (IRD) are a leading cause of blindness in the working age population. The advances in ocular genetics, retinal imaging and molecular biology, have conspired to create the ideal environment for establishing treatments for IRD, with the first approved gene therapy and the commencement of multiple therapy trials. The scope of this review is to familiarize clinicians and scientists with the current landscape of retinal imaging in IRD. Herein we present in a comprehensive and concise manner the imaging findings of: (I) macular dystrophies (MD) [Stargardt disease (ABCA4), X-linked retinoschisis (RS1), Best disease (BEST1), pattern dystrophy (PRPH2), Sorsby fundus dystrophy (TIMP3), and autosomal dominant drusen (EFEMP1)], (II) cone and cone-rod dystrophies (GUCA1A, PRPH2, ABCA4 and RPGR), (III) cone dysfunction syndromes [achromatopsia (CNGA3, CNGB3, PDE6C, PDE6H, GNAT2, ATF6], blue-cone monochromatism (OPN1LW/OPN1MW array), oligocone trichromacy, bradyopsia (RGS9/R9AP) and Bornholm eye disease (OPN1LW/OPN1MW), (IV) Leber congenital amaurosis (GUCY2D, CEP290, CRB1, RDH12, RPE65, TULP1, AIPL1 and NMNAT1), (V) rod-cone dystrophies [retinitis pigmentosa, enhanced S-Cone syndrome (NR2E3), Bietti crystalline corneoretinal dystrophy (CYP4V2)], (VI) rod dysfunction syndromes (congenital stationary night blindness, fundus albipunctatus (RDH5), Oguchi disease (SAG, GRK1), and (VII) chorioretinal dystrophies [choroideremia (CHM), gyrate atrophy (OAT)].

遗传性视网膜疾病(IRD)是劳动适龄人口失明的主要原因。眼部遗传学、视网膜成像和分子生物学的进步为建立 IRD 治疗方法创造了理想的环境,首例基因疗法获得批准,多项治疗试验也已开始。本综述的目的是让临床医生和科学家了解目前 IRD 视网膜成像的发展状况。在此,我们将以全面而简洁的方式介绍以下方面的成像结果:(I) 黄斑营养不良症(MD)[Stargardt 病(ABCA4)、X 连锁视网膜裂孔症(RS1)、Best 病(BEST1)、模式营养不良症(PRPH2)、Sorsby 眼底营养不良症(TIMP3)和常染色体显性葡萄肿(EFEMP1)],(II) 锥体和锥杆状营养不良症(GUCA1A、PRPH2、ABCA4 和 RPGR),(III) 锥体功能障碍综合征[色觉减退症(CNGA3、CNGB3、PDE6C、PDE6H、GNAT2、ATF6]、蓝锥体单色症(OPN1LW/OPN1MW 阵列)、寡锥体三色症、盲视症(RGS9/R9AP)和博恩霍姆眼病(OPN1LW/OPN1MW)、(IV) Leber 先天性失明(GUCY2D、CEP290、CRB1、RDH12、RPE65、TULP1、AIPL1 和 NMNAT1), (V) 视杆-视锥营养不良症[色素性视网膜炎、S-视锥增强综合征(NR2E3)、Bietti 晶状体角膜营养不良症(CYP4V2)]、(VII) 脉络膜视网膜营养不良症[脉络膜血症(CHM)、回旋肌萎缩症(OAT)]。
{"title":"Retinal imaging in inherited retinal diseases.","authors":"Michalis Georgiou, Kaoru Fujinami, Michel Michaelides","doi":"10.21037/aes-20-81","DOIUrl":"10.21037/aes-20-81","url":null,"abstract":"<p><p>Inherited retinal diseases (IRD) are a leading cause of blindness in the working age population. The advances in ocular genetics, retinal imaging and molecular biology, have conspired to create the ideal environment for establishing treatments for IRD, with the first approved gene therapy and the commencement of multiple therapy trials. The scope of this review is to familiarize clinicians and scientists with the current landscape of retinal imaging in IRD. Herein we present in a comprehensive and concise manner the imaging findings of: (I) macular dystrophies (MD) [Stargardt disease (<i>ABCA4</i>), X-linked retinoschisis (<i>RS1</i>), Best disease (<i>BEST1</i>), pattern dystrophy (<i>PRPH2</i>), Sorsby fundus dystrophy (<i>TIMP3</i>), and autosomal dominant drusen (<i>EFEMP1</i>)], (II) cone and cone-rod dystrophies (<i>GUCA1A</i>, <i>PRPH2</i>, <i>ABCA4</i> and <i>RPGR</i>)<i>,</i> (III) cone dysfunction syndromes [achromatopsia (<i>CNGA3, CNGB3, PDE6C, PDE6H, GNAT2, ATF6</i>], blue-cone monochromatism (<i>OPN1LW/OPN1MW</i> array), oligocone trichromacy, bradyopsia (<i>RGS9/R9AP</i>) and Bornholm eye disease (<i>OPN1LW/OPN1MW</i>), (IV) Leber congenital amaurosis (<i>GUCY2D</i>, <i>CEP290</i>, <i>CRB1</i>, <i>RDH12</i>, <i>RPE65, TULP1</i>, <i>AIPL1</i> and <i>NMNAT1</i>)<i>,</i> (V) rod-cone dystrophies [retinitis pigmentosa, enhanced S-Cone syndrome (<i>NR2E3</i>), Bietti crystalline corneoretinal dystrophy (<i>CYP4V2</i>)], (VI) rod dysfunction syndromes (congenital stationary night blindness, fundus albipunctatus (<i>RDH5</i>)<i>,</i> Oguchi disease (<i>SAG</i>, <i>GRK1</i>), and (VII) chorioretinal dystrophies [choroideremia (<i>CHM</i>), gyrate atrophy (<i>OAT</i>)].</p>","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"5 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/2a/nihms-1685213.PMC8081382.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38933705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the Diagnosis and Management of Acute Retinal Necrosis. 急性视网膜坏死诊治进展》。
Pub Date : 2020-09-01 Epub Date: 2020-09-15 DOI: 10.21037/aes-2019-dmu-09
Casey L Anthony, J Clay Bavinger, Steven Yeh

Acute retinal necrosis (ARN) is a devastating syndrome characterized by panuveitis, retinal necrosis, and a high rate of retinal detachment that may result in poor visual outcomes if not promptly diagnosed and treated. ARN is most commonly caused by viruses with the herpesvirus family. Etiologies include varicella-zoster virus, herpes simplex virus, and cytomegalovirus, and may be promptly diagnosed by polymerase chain reaction testing of aqueous or vitreous fluid. The true incidence of ARN is not known due to its rarity; as a result, clinical treatment is often guided by retrospective case series, case reports, and expert opinion. Standard of care has evolved over time but currently includes a combination of systemic and intravitreal antiviral in conjunction with topical or oral steroids and surgical therapy as needed. Combination therapy may reduce the rate of severe vision loss and increase the rate of visual acuity gain, although further studies are needed in this area. In particular for patients with mild to moderate disease, combination therapy may reduce the rate of retinal detachment. Adjunctive therapies including oral corticosteroid and prophylactic laser barricade are incompletely studied, but corticosteroid in particular, may reduce inflammation, which also is involved in the severe disease pathogenesis observed in ARN. This review discusses the advances in diagnosis and treatment of ARN, including management with combination antiviral medication and surgical interventions.

急性视网膜坏死(ARN)是一种破坏性综合征,其特征是泛眼炎、视网膜坏死和高视网膜脱离率,如果不及时诊断和治疗,可能会导致不良的视力后果。ARN 最常见的病因是疱疹病毒科的病毒。病因包括水痘-带状疱疹病毒、单纯疱疹病毒和巨细胞病毒,可通过对水液或玻璃体液进行聚合酶链反应检测而迅速确诊。由于 ARN 的罕见性,其真实发病率尚不清楚;因此,临床治疗通常以回顾性系列病例、病例报告和专家意见为指导。随着时间的推移,治疗标准也在不断变化,但目前包括全身和玻璃体内抗病毒治疗、局部或口服类固醇以及必要的手术治疗。联合疗法可降低严重视力丧失率,提高视力恢复率,但这方面还需要进一步研究。特别是对于轻度至中度患者,联合疗法可能会降低视网膜脱离的发生率。包括口服皮质类固醇和预防性激光障眼法在内的辅助疗法尚未得到全面研究,但皮质类固醇尤其可以减轻炎症,而炎症也与 ARN 中观察到的严重疾病发病机制有关。本综述讨论了 ARN 诊断和治疗方面的进展,包括联合抗病毒药物治疗和手术干预。
{"title":"Advances in the Diagnosis and Management of Acute Retinal Necrosis.","authors":"Casey L Anthony, J Clay Bavinger, Steven Yeh","doi":"10.21037/aes-2019-dmu-09","DOIUrl":"10.21037/aes-2019-dmu-09","url":null,"abstract":"<p><p>Acute retinal necrosis (ARN) is a devastating syndrome characterized by panuveitis, retinal necrosis, and a high rate of retinal detachment that may result in poor visual outcomes if not promptly diagnosed and treated. ARN is most commonly caused by viruses with the herpesvirus family. Etiologies include varicella-zoster virus, herpes simplex virus, and cytomegalovirus, and may be promptly diagnosed by polymerase chain reaction testing of aqueous or vitreous fluid. The true incidence of ARN is not known due to its rarity; as a result, clinical treatment is often guided by retrospective case series, case reports, and expert opinion. Standard of care has evolved over time but currently includes a combination of systemic and intravitreal antiviral in conjunction with topical or oral steroids and surgical therapy as needed. Combination therapy may reduce the rate of severe vision loss and increase the rate of visual acuity gain, although further studies are needed in this area. In particular for patients with mild to moderate disease, combination therapy may reduce the rate of retinal detachment. Adjunctive therapies including oral corticosteroid and prophylactic laser barricade are incompletely studied, but corticosteroid in particular, may reduce inflammation, which also is involved in the severe disease pathogenesis observed in ARN. This review discusses the advances in diagnosis and treatment of ARN, including management with combination antiviral medication and surgical interventions.</p>","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"5 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771653/pdf/nihms-1623169.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39115100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optical coherence tomography use in idiopathic intracranial hypertension. 光学相干断层扫描在特发性颅内高压中的应用。
Pub Date : 2020-03-01 Epub Date: 2020-03-15 DOI: 10.21037/aes.2019.12.06
Kiran Malhotra, Tanyatuth Padungkiatsagul, Heather E Moss

Idiopathic intracranial hypertension (IIH) is a condition in which elevated pressure in the cerebrospinal fluid can lead to optic nerve head (ONH) dysfunction and subsequent visual impairment. Physicians are currently limited in their ability to monitor and manage this condition, as clinical symptoms and exam findings are often delayed in response to changes in intracranial pressure. In order to find other biomarkers of disease, researchers are using imaging modalities such as optical coherence tomography (OCT) to observe microscopic changes in the eye in this condition. OCT can create 2-dimensional and 3-dimensional high definition images of the retina of the ONH and has been used to study various conditions such as glaucoma and multiple sclerosis. Numerous studies have used OCT in IIH as well, and they have shown that certain retinal layers and the ONH change in thickness and shape in both the short and long term with intracranial pressure changes. OCT is a promising modality for clinical and scientific evaluation of IIH as it is a noninvasive and practical tool to obtain in depth images. This review will discuss how OCT can be used to assess a patient with IIH, both before and after treatment, along with its limitations and future applications.

特发性颅内高压(IIH)是一种脑脊液压力升高可导致视神经头(ONH)功能障碍和随后的视力损害的疾病。由于临床症状和检查结果对颅内压变化的反应往往延迟,医生目前监测和治疗这种疾病的能力有限。为了找到疾病的其他生物标志物,研究人员正在使用光学相干断层扫描(OCT)等成像方式来观察这种情况下眼睛的微观变化。OCT可以创建ONH视网膜的二维和三维高清图像,并已用于研究各种疾病,如青光眼和多发性硬化症。大量的研究也使用了OCT在IIH中,他们已经表明,某些视网膜层和ONH在短期和长期内随着颅内压的变化而改变厚度和形状。OCT是临床和科学评估IIH的一种很有前途的方式,因为它是一种无创和实用的工具,可以获得深度图像。本文将讨论OCT在治疗前后如何用于评估IIH患者,以及其局限性和未来应用。
{"title":"Optical coherence tomography use in idiopathic intracranial hypertension.","authors":"Kiran Malhotra, Tanyatuth Padungkiatsagul, Heather E Moss","doi":"10.21037/aes.2019.12.06","DOIUrl":"10.21037/aes.2019.12.06","url":null,"abstract":"<p><p>Idiopathic intracranial hypertension (IIH) is a condition in which elevated pressure in the cerebrospinal fluid can lead to optic nerve head (ONH) dysfunction and subsequent visual impairment. Physicians are currently limited in their ability to monitor and manage this condition, as clinical symptoms and exam findings are often delayed in response to changes in intracranial pressure. In order to find other biomarkers of disease, researchers are using imaging modalities such as optical coherence tomography (OCT) to observe microscopic changes in the eye in this condition. OCT can create 2-dimensional and 3-dimensional high definition images of the retina of the ONH and has been used to study various conditions such as glaucoma and multiple sclerosis. Numerous studies have used OCT in IIH as well, and they have shown that certain retinal layers and the ONH change in thickness and shape in both the short and long term with intracranial pressure changes. OCT is a promising modality for clinical and scientific evaluation of IIH as it is a noninvasive and practical tool to obtain in depth images. This review will discuss how OCT can be used to assess a patient with IIH, both before and after treatment, along with its limitations and future applications.</p>","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"5 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/aes.2019.12.06","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37932860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Focal alteration of the intraretinal layers in neurodegenerative disorders. 神经退行性疾病视网膜内层的局灶性改变。
Pub Date : 2020-03-01 DOI: 10.21037/aes.2019.12.04
Shriya Airen, Ce Shi, Zhiping Liu, Bonnie E Levin, Joseph F Signorile, Jianhua Wang, Hong Jiang

Focal intraretinal alterations have been studied to advance our understanding of the pathology of neurodegenerative diseases. The current literature involving focal alterations in the intraretinal layers was reviewed through PubMed using the search terms "focal alteration", "region of interest", "optical coherence tomography", "glaucoma", "multiple sclerosis", "Alzheimer's disease", "Parkinson disease", "neurodegenerative diseases" and other related items. It was found that focal alterations of intraretinal layers were different in various neurodegenerative diseases. The typical focal thinning might help differentiate various ocular and cerebral diseases, track disease progression, and evaluate the outcome of clinical trials. Advanced exploration of focal intraretinal alterations will help to further validate their clinical and research utility.

局灶性视网膜内改变已被研究,以提高我们对神经退行性疾病病理的理解。通过PubMed检索“局灶性改变”、“感兴趣区域”、“光学相干断层扫描”、“青光眼”、“多发性硬化症”、“阿尔茨海默病”、“帕金森病”、“神经退行性疾病”等相关词条,对目前涉及视网膜内层局灶性改变的文献进行综述。发现不同神经退行性疾病的视网膜内层局灶性改变不同。典型的灶变薄可能有助于区分各种眼和脑疾病,跟踪疾病进展,并评估临床试验的结果。对局灶性视网膜内病变的深入研究将有助于进一步验证其临床和研究的实用性。
{"title":"Focal alteration of the intraretinal layers in neurodegenerative disorders.","authors":"Shriya Airen,&nbsp;Ce Shi,&nbsp;Zhiping Liu,&nbsp;Bonnie E Levin,&nbsp;Joseph F Signorile,&nbsp;Jianhua Wang,&nbsp;Hong Jiang","doi":"10.21037/aes.2019.12.04","DOIUrl":"https://doi.org/10.21037/aes.2019.12.04","url":null,"abstract":"<p><p>Focal intraretinal alterations have been studied to advance our understanding of the pathology of neurodegenerative diseases. The current literature involving focal alterations in the intraretinal layers was reviewed through PubMed using the search terms \"focal alteration\", \"region of interest\", \"optical coherence tomography\", \"glaucoma\", \"multiple sclerosis\", \"Alzheimer's disease\", \"Parkinson disease\", \"neurodegenerative diseases\" and other related items. It was found that focal alterations of intraretinal layers were different in various neurodegenerative diseases. The typical focal thinning might help differentiate various ocular and cerebral diseases, track disease progression, and evaluate the outcome of clinical trials. Advanced exploration of focal intraretinal alterations will help to further validate their clinical and research utility.</p>","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"5 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/aes.2019.12.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38485378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Acute retinal arterial ischemia. 急性视网膜动脉缺血。
Pub Date : 2018-06-01 Epub Date: 2018-06-06 DOI: 10.21037/aes.2018.05.04
Michael Dattilo, Nancy J Newman, Valérie Biousse

Acute retinal arterial ischemia, which includes transient monocular vision loss (TMVL), branch retinal artery occlusion (BRAO), central retinal artery occlusion (CRAO) and ophthalmic artery occlusion (OAO), is most commonly the consequence of an embolic phenomenon from the ipsilateral carotid artery, heart or aortic arch, leading to partial or complete occlusion of the central retinal artery (CRA) or its branches. Acute retinal arterial ischemia is the ocular equivalent of acute cerebral ischemia and is an ophthalmic and medical emergency. Patients with acute retinal arterial ischemia are at a high risk of having further vascular events, such as subsequent strokes and myocardial infarctions (MIs). Therefore, prompt diagnosis and urgent referral to appropriate specialists and centers is necessary for further work-up (such as brain magnetic resonance imaging with diffusion weighted imaging, vascular imaging, and cardiac monitoring and imaging) and potential treatment of an urgent etiology (e.g., carotid dissection or critical carotid artery stenosis). Since there are no proven, effective treatments to improve visual outcome following permanent retinal arterial ischemia (central or branch retinal artery occlusion), treatment must focus on secondary prevention measures to decrease the likelihood of subsequent ischemic events.

急性视网膜动脉缺血,包括短暂性单眼视力丧失(TMVL)、视网膜分支动脉闭塞(BRAO)、视网膜中央动脉闭塞(CRAO)和眼动脉闭塞(OAO),最常见的是同侧颈动脉、心脏或主动脉弓的栓塞现象,导致视网膜中央动脉(CRA)或其分支部分或完全闭塞。急性视网膜动脉缺血相当于急性脑缺血,是眼科和医疗紧急情况。急性视网膜动脉缺血患者发生进一步血管事件的风险很高,如随后的中风和心肌梗死(MIs)。因此,及时诊断和紧急转诊到适当的专家和中心是必要的,以便进一步检查(如脑磁共振扩散加权成像、血管成像和心脏监测和成像)和潜在的紧急病因治疗(如颈动脉夹层或颈动脉严重狭窄)。由于没有经过证实的有效治疗方法来改善永久性视网膜动脉缺血(视网膜中央或分支动脉闭塞)后的视力结果,治疗必须侧重于二级预防措施,以减少随后缺血性事件的可能性。
{"title":"Acute retinal arterial ischemia.","authors":"Michael Dattilo,&nbsp;Nancy J Newman,&nbsp;Valérie Biousse","doi":"10.21037/aes.2018.05.04","DOIUrl":"https://doi.org/10.21037/aes.2018.05.04","url":null,"abstract":"<p><p>Acute retinal arterial ischemia, which includes transient monocular vision loss (TMVL), branch retinal artery occlusion (BRAO), central retinal artery occlusion (CRAO) and ophthalmic artery occlusion (OAO), is most commonly the consequence of an embolic phenomenon from the ipsilateral carotid artery, heart or aortic arch, leading to partial or complete occlusion of the central retinal artery (CRA) or its branches. Acute retinal arterial ischemia is the ocular equivalent of acute cerebral ischemia and is an ophthalmic and medical emergency. Patients with acute retinal arterial ischemia are at a high risk of having further vascular events, such as subsequent strokes and myocardial infarctions (MIs). Therefore, prompt diagnosis and urgent referral to appropriate specialists and centers is necessary for further work-up (such as brain magnetic resonance imaging with diffusion weighted imaging, vascular imaging, and cardiac monitoring and imaging) and potential treatment of an urgent etiology (e.g., carotid dissection or critical carotid artery stenosis). Since there are no proven, effective treatments to improve visual outcome following permanent retinal arterial ischemia (central or branch retinal artery occlusion), treatment must focus on secondary prevention measures to decrease the likelihood of subsequent ischemic events.</p>","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"3 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/aes.2018.05.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36477163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 43
Case 01-2017 - Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016. 病例01-2017 -原发性玻璃体视网膜淋巴瘤(PVRL): 1例报告及1942 - 2016年文献更新
Pub Date : 2017-07-01 DOI: 10.21037/aes.2017.06.06
Yujuan Wang, Dik S Cheung, Chi-Chao Chan

Primary vitreoretinal lymphoma (PVRL), as a subset of primary central nervous system lymphoma (PCNSL), is a rare and fatal ocular malignancy. Most PVRL masquerades as chronic posterior uveitis, which makes the clinical diagnosis challenging. Vitreous cells, subretinal lesions and imaging techniques are essential for clinical diagnosis. Importantly, cytopathology/histopathology identification of malignant cells is the gold standard for the diagnosis of PVRL. In addition, molecular detection of immunoglobulin heavy chain (IgH) or T cell receptor (TCR) gene rearrangements, immunophenotyping for cell markers, and cytokine analysis of interleukine-10 elevation are often used as adjunct procedures. Current management of PVRL involves local radiation, intravitreal chemotherapy (methotrexate and rituximab), with or without systemic chemotherapy depending on the involvement of non-ocular tissues. In cases with concomitant PCNSL, systemic high-dose methotrexate/rituximab based therapy in conjunction with local therapy, whole brain radiotherapy and/or autologous stem cell transplantation is considered. Although PVRL normally responds well to initial treatment, high rates of relapse and CNS involvement usually lead to poor prognosis and limited survival. A professional team of medical experts in ophthalmologists, ocular pathologists, neuro-oncologists and hemato-oncologists is essential for optimizing patient management.

原发性玻璃体视网膜淋巴瘤(PVRL)作为原发性中枢神经系统淋巴瘤(PCNSL)的一个亚群,是一种罕见且致命的眼部恶性肿瘤。大多数PVRL伪装成慢性后葡萄膜炎,这使得临床诊断具有挑战性。玻璃体细胞、视网膜下病变和成像技术是临床诊断的必要条件。重要的是,恶性细胞的细胞病理学/组织病理学鉴定是诊断PVRL的金标准。此外,免疫球蛋白重链(IgH)或T细胞受体(TCR)基因重排的分子检测、细胞标记物的免疫分型和白细胞介素-10升高的细胞因子分析通常被用作辅助程序。目前PVRL的治疗包括局部放疗、玻璃体内化疗(甲氨蝶呤和利妥昔单抗),根据是否累及非眼部组织,进行或不进行全身化疗。在合并PCNSL的病例中,考虑全身高剂量甲氨蝶呤/美罗华治疗联合局部治疗、全脑放疗和/或自体干细胞移植。虽然PVRL通常对初始治疗反应良好,但高复发率和累及中枢神经系统通常导致预后差和生存期有限。由眼科医生、眼科病理学家、神经肿瘤学家和血液肿瘤学家组成的专业医疗专家团队对于优化患者管理至关重要。
{"title":"Case 01-2017 - Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016.","authors":"Yujuan Wang,&nbsp;Dik S Cheung,&nbsp;Chi-Chao Chan","doi":"10.21037/aes.2017.06.06","DOIUrl":"https://doi.org/10.21037/aes.2017.06.06","url":null,"abstract":"<p><p>Primary vitreoretinal lymphoma (PVRL), as a subset of primary central nervous system lymphoma (PCNSL), is a rare and fatal ocular malignancy. Most PVRL masquerades as chronic posterior uveitis, which makes the clinical diagnosis challenging. Vitreous cells, subretinal lesions and imaging techniques are essential for clinical diagnosis. Importantly, cytopathology/histopathology identification of malignant cells is the gold standard for the diagnosis of PVRL. In addition, molecular detection of <i>immunoglobulin heavy chain (IgH)</i> or <i>T cell receptor (TCR)</i> gene rearrangements, immunophenotyping for cell markers, and cytokine analysis of interleukine-10 elevation are often used as adjunct procedures. Current management of PVRL involves local radiation, intravitreal chemotherapy (methotrexate and rituximab), with or without systemic chemotherapy depending on the involvement of non-ocular tissues. In cases with concomitant PCNSL, systemic high-dose methotrexate/rituximab based therapy in conjunction with local therapy, whole brain radiotherapy and/or autologous stem cell transplantation is considered. Although PVRL normally responds well to initial treatment, high rates of relapse and CNS involvement usually lead to poor prognosis and limited survival. A professional team of medical experts in ophthalmologists, ocular pathologists, neuro-oncologists and hemato-oncologists is essential for optimizing patient management.</p>","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"2 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/aes.2017.06.06","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36450197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The good doctor: more than medical knowledge & surgical skill. 好医生:不仅仅是医学知识和外科技能。
Pub Date : 2017-07-01 Epub Date: 2017-07-04 DOI: 10.21037/aes.2017.05.04
Andreas K Lauer, Dariah A Lauer
You have worked hard in school over many years to excel in academic and extracurricular activities. You submitted a strong application for successful entry into medical school during which time you doubled up on your academic productivity and soaked in everything that you could possibly learn about medicine. You feel that your academic productivity paid off since you were able to obtain a residency in your favorite field: ophthalmology.
{"title":"The good doctor: more than medical knowledge & surgical skill.","authors":"Andreas K Lauer,&nbsp;Dariah A Lauer","doi":"10.21037/aes.2017.05.04","DOIUrl":"10.21037/aes.2017.05.04","url":null,"abstract":"You have worked hard in school over many years to excel in academic and extracurricular activities. You submitted a strong application for successful entry into medical school during which time you doubled up on your academic productivity and soaked in everything that you could possibly learn about medicine. You feel that your academic productivity paid off since you were able to obtain a residency in your favorite field: ophthalmology.","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"2 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/aes.2017.05.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36516201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Program & faculty evaluation. 项目和教师评估。
Pub Date : 2017-07-01 Epub Date: 2017-07-04 DOI: 10.21037/aes.2017.06.02
Andreas K Lauer

Graduate medical education (GME) has shifted its curricula from process-oriented approach to outcomes-oriented models. Program and faculty evaluation are methods by which educational curricula may adjust the teaching and learning environment to meet the needs and fills the gaps in GME. The measurement of educational outcomes is an essential for assessing teaching effectiveness in a shifting health care environment. In addition to trainee, program, and faculty evaluations, annual program review (APR) and evaluation and navigational changes made by the program education committee are essential to maintain effectiveness of an educational curriculum in a contemporary graduate medical training program.

研究生医学教育(GME)已将其课程从面向过程的方法转向面向结果的模式。课程评估和教师评估是教育课程调整教学环境以满足GME需求和填补其空白的方法。在不断变化的卫生保健环境中,衡量教育成果对于评估教学效果至关重要。除了对实习生、项目和教员的评估外,项目教育委员会所做的年度项目审查(APR)和评估以及导航性变更对于保持当代研究生医学培训项目教育课程的有效性至关重要。
{"title":"Program & faculty evaluation.","authors":"Andreas K Lauer","doi":"10.21037/aes.2017.06.02","DOIUrl":"https://doi.org/10.21037/aes.2017.06.02","url":null,"abstract":"<p><p>Graduate medical education (GME) has shifted its curricula from process-oriented approach to outcomes-oriented models. Program and faculty evaluation are methods by which educational curricula may adjust the teaching and learning environment to meet the needs and fills the gaps in GME. The measurement of educational outcomes is an essential for assessing teaching effectiveness in a shifting health care environment. In addition to trainee, program, and faculty evaluations, annual program review (APR) and evaluation and navigational changes made by the program education committee are essential to maintain effectiveness of an educational curriculum in a contemporary graduate medical training program.</p>","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"2 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/aes.2017.06.02","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36516200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Multifunctional nanotherapeutics for treatment of ocular disease. 用于眼部疾病治疗的多功能纳米疗法。
Pub Date : 2017-04-01 Epub Date: 2017-04-28 DOI: 10.21037/aes.2017.03.06
Tian Xia
{"title":"Multifunctional nanotherapeutics for treatment of ocular disease.","authors":"Tian Xia","doi":"10.21037/aes.2017.03.06","DOIUrl":"10.21037/aes.2017.03.06","url":null,"abstract":"","PeriodicalId":8400,"journal":{"name":"Annals of Eye Science","volume":"2 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36411693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of Eye Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1